Esperion (ESPR) AI Stock Analysis

• Market Cap: $231.89M
• Dividend Yield: N/A
• Average Volume (3M): 3.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.48
• Revenue Growth: 12.99%
• EPS Growth: 17.78%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.21
• Shares Outstanding: 198,199,460
• 10 Day Avg. Volume: 3,066,394
• 30 Day Avg. Volume: 3,645,698
• PEG Ratio: 0.02
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.37
• Enterprise Value/Market Cap: 2.37
• Enterprise Value/Revenue: 0.47
• Enterprise Value/Gross Profit: 3.24
• Enterprise Value/Ebitda: -3.66
• 1Y Price Target: $6.37
• Price Target Upside: 444.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 50 Neutral
• Price Target: $1.00 ▼(-14.53%Downside)

Esperion's overall stock score is primarily impacted by its financial instability and negative valuation metrics. Despite strong revenue growth and positive corporate events, significant risks remain due to ongoing profitability challenges and high leverage. Technical analysis and earnings call insights provide some positive outlook, but the financial health concerns weigh heavily on the score.

Positive Factors

Market Growth

Early 2Q25 trends for BDA sales are encouraging based on prescription volume tracking approximately 8% higher than 1Q25.

Strategic Partnerships

Esperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada, reflecting the company's commitment to expand BDA’s global access and position its product for meaningful long-term growth.

Negative Factors

Legal Challenges

The settlements with ANDA filers help avoid costly and lengthy legal processes typically associated with patent disputes.

Patent Settlements

Esperion has reached a settlement with a second Abbreviated New Drug Application (ANDA) filer for Nexletol, precluding generic marketing until April 19, 2040, preventing the typical multi-year process of suing, summary judgement, and appeals.

Esperion Business Overview & Revenue Model

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

How the Company Makes Money

Esperion generates revenue primarily through the sale of its FDA-approved cholesterol-lowering medications, NEXLETOL and NEXLIZET, across various markets. The company earns money by distributing these products to healthcare providers, pharmacies, and hospitals, where they are prescribed to patients with high LDL-C levels who are either statin-intolerant or require additional cholesterol-lowering treatments. Esperion also engages in strategic partnerships and collaborations with other pharmaceutical companies to expand the reach and commercialization of its products in international markets, contributing to its revenue streams. Additionally, the company may receive milestone payments and royalties from these partnerships, which further bolster its financial performance.

Esperion Financial Statement Overview

Summary

Esperion demonstrates strong revenue growth, but faces significant profitability challenges with ongoing negative net income and high debt levels. The reliance on debt and negative equity position pose financial risks, and while cash flows are improving, they remain negative.

Income Statement

Esperion's revenue increased significantly from 2023 to 2024, demonstrating a strong growth trajectory in the income statement. However, the company continues to face challenges with profitability, as evidenced by negative net income, resulting in a negative net profit margin. The gross profit margin remains high, indicating efficient cost management relative to revenue, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows significant financial leverage with a negative stockholders' equity, indicating potential financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which is a red flag. Total debt is substantial, and the equity ratio is negative, suggesting the company is heavily reliant on debt financing. The negative return on equity further highlights profitability challenges.

Cash Flow

Esperion's cash flow statement reveals improving free cash flow, although it remains negative. Operating cash flow is also negative, which raises concerns about the sustainability of operations without external financing. The free cash flow to net income ratio is not favorable due to persistent losses, though the operating cash flow to net income ratio suggests some efficiency in cash management relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	259.57M	332.31M	116.33M	75.47M	78.45M	227.55M
Gross Profit	169.51M	263.71M	73.07M	48.51M	64.23M	225.16M
EBITDA	-88.47M	7.57M	-150.11M	-176.35M	-222.14M	-120.33M
Net Income	-153.22M	-51.74M	-209.25M	-287.82M	-318.82M	-166.19M
Balance Sheet
Total Assets	324.03M	343.82M	205.80M	247.94M	381.59M	353.26M
Cash, Cash Equivalents and Short-Term Investments	114.63M	144.76M	82.25M	124.78M	208.89M	304.96M
Total Debt	297.78M	297.60M	540.95M	260.95M	260.20M	185.41M
Total Liabilities	750.24M	732.54M	660.79M	571.72M	578.53M	449.39M
Stockholders Equity	-426.21M	-388.72M	-454.99M	-1.34B	-1.11B	-838.82M
Cash Flow
Free Cash Flow	-100.35M	-23.97M	-135.49M	-174.83M	-263.81M	-98.55M
Operating Cash Flow	-100.11M	-23.65M	-135.49M	-174.83M	-263.81M	-85.18M
Investing Cash Flow	-244.00K	-317.00K	42.50M	8.10M	-50.48M	21.36M
Financing Cash Flow	-11.62M	86.48M	50.46M	32.61M	268.22M	201.72M

Esperion Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.17
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Positive. The current price of 1.17 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 0.98, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 66.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ESPR.

Esperion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	56 Neutral	$379.40M	―	-21.63%	―	-18.56%	76.88%
DERM	54 Neutral	$165.40M	―	-48.14%	―	-29.69%	-105.88%
LFCR	51 Neutral	$297.68M	―	-83.58%	―	6.88%	-17.54%
AQST	51 Neutral	$369.50M	―	77.48%	―	5.29%	-37.31%
ESPR	50 Neutral	$231.89M	―	23.44%	―	12.99%	17.78%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
IRWD	45 Neutral	$123.95M	85.74	-8.02%	―	-23.18%	97.12%

Esperion Corporate Events

Esperion Expands Board with New Appointment

On July 1, 2025, Esperion announced the appointment of Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson’s extensive experience in biopharmaceutical leadership is expected to enhance Esperion’s strategic direction as it continues to innovate in cardiovascular and cardiometabolic drug development, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.

Esperion Gains Strong Shareholder Support at Annual Meeting

On May 29, 2025, Esperion held its Annual Meeting where stockholders voted on several key proposals. These included the election of two Class III director nominees, approval of executive compensation, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and an amendment to increase shares under the 2022 Plan. All proposals were approved, indicating strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.